Digoxin Immune Fab

Digoxin Immune Fab (DigiFab) is used to treat digoxin toxicity and other cardiac glycoside poisoning

Dresentation

Indications

Digoxin toxicity (acute and chronic)

- See digoxin guideline for indications

Other cardiac glycosides poisoning

- e.g., oleander, foxglove, cane toad

(Discuss with clinical toxicologist)

Contraindications:

- Known hypersensitivity

Adverse effects: (rare)

- mild urticarial rash and facial swelling
- flu-like illness
- with rapid reversal of digoxin effect:
 - exacerbation of congestive heart failure
 - rapid ventricular response in atrial fibrillation
 - hypokalaemia
- hypotension
- chest pain

Pregnancy: Safety not established, but

administration should not be withheld if

indicated

AUSTIN CLINICAL TOXICOLOGY SERVICE GUIDELINE

	I resentation
	- Digoxin specific antibody fragment - 40 mg / vial
	Dose and Administration
	- 40 mg of Digoxin specific antibody fragment binds \sim 0.5 mg of digoxin; variable binding to
	plant and animal cardiac glycosides
1	- Calculations to determine the dose are no longer recommended as they overestimate dose required.
	- Dose depends on cardiovascular status of patient (cardiac arrest or non-arrest):
	- <u>CARDIAC ARREST</u> : (Call clinical toxicologist AND treat as per ALS protocols)
	Secondary to ACUTE digoxin overdose: 5 vials as IV push and repeat in 5-10 minutes
	- If ROSC not achieved, discuss requirement for > 10 vials with clinical toxicologist
	Secondary to CHRONIC digoxin accumulation (e.g., renal failure / dosing change):
	2 vials as IV push every 5-10 minutes (discuss requirement for > 4 vials with clinical toxicologist)
re	- <u>Not in Cardiac Arrest</u>
orillation	1-2 vials in 100 mL of N/Saline infused over 15 - 30 minutes. Repeat doses may be required.
	(guided by ECG changes, haemodynamic state and K+ concentration - discuss with clinical toxicologist)
	Total serum digoxin concentration is not interpretable after administration of digoxin immune Fab
	- Clinical response is usually evident within an hour post administration
	- Monitor patient for at least 12 hours post administration of DigiFab.
	Therapeutic Endpoint:
	- Resolution of cardiotoxicity

POISONS INFORMATION CENTRE: 13 11 26